PharmGen Science, Inc. (KRX:004720)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,755.00
+105.00 (2.88%)
Last updated: Mar 11, 2026, 3:00 PM KST
Market Cap82.28B +5.4%
Revenue (ttm)171.66B -0.0%
Net Income117.75M -98.2%
EPS6.50 -98.1%
Shares Out21.91M
PE Ratio698.78
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume92,795
Average Volume110,614
Open3,690.00
Previous Close3,650.00
Day's Range3,650.00 - 3,835.00
52-Week Range3,410.00 - 5,490.00
Beta0.29
RSI41.25
Earnings DateMar 20, 2026

About PharmGen Science

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea. [Read more]

Sector Healthcare
Founded 1957
Employees 226
Stock Exchange Korea Stock Exchange
Ticker Symbol 004720
Full Company Profile

Financial Performance

In 2024, PharmGen Science's revenue was 171.29 billion, an increase of 2.70% compared to the previous year's 166.78 billion. Earnings were 2.79 billion, a decrease of -54.17%.

Financial Statements